Skip to content

DuPont de Nemours

NYSE: DD · USD

DuPont de Nemours (DD) Economic Moat Analysis—

Competitive advantages, dated evidence and erosion risks.

Uncertain economic moat

DuPont has usable intellectual property and operates in markets requiring complex regulatory approvals, but the passages do not establish durable competitive exclusion or customer dependence. Second-quarter 2026 sales, operating EBITDA and cash generation improved; price, volume and mix are insufficiently separated to assess realized pricing. Completed portfolio transactions demonstrate execution, not achieved investment returns. The evidence supports potential intangible-asset advantages, while leaving their economic strength and durability uncertain. It establishes neither a durable company-wide moat nor realized competitive weakness sufficient for a no-moat verdict.

Intangible assets

Potential advantage only: DuPont retains access to patents, know-how and other intellectual property through its post-separation arrangements. Complex product approvals could reinforce technical differentiation, but neither contractual IP access nor regulatory obligations demonstrate superiority over competitors.

Durability
Unestablished. The passages provide neither remaining protection periods nor evidence that approvals or proprietary technology sustain customer preference and economic rents.
Competitors
Comparison not established
Erosion risks
IP challenges can constrain commercialization; approval requirements change and require renewal. Passing costs through to customers depends on competitive conditions. These disclosed risks are possibilities, not proof of realized erosion.
What would invalidate the thesis
The candidate advantage would be undermined by disclosed substitution of competing products without material qualification costs, loss of commercially essential IP rights or approvals, or persistent price concessions attributable to competing alternatives.
Evidence (3) · Counterevidence (3)

Changes since the previous analysis

  • The uncertain verdict is unchanged; the current catalog does not substantiate the previous analysis's patent-scale or specialized-capability claims.
  • Realized_pricing changes from 2 to null because the historical price/mix and net-pricing passages previously cited are absent. Current organic growth does not isolate pricing.
  • Margin_resilience remains 2 using current second-quarter operating results rather than the unavailable historical segment comparisons.
  • Capital_discipline, incentive_alignment and execution remain 2, with their arguments rebuilt from current excerpts. Previous claims about below-threshold adjusted ROIC and PSU conversion are not retained because their supporting passages are absent.
  • Governance remains 3 using disclosed governance practices, actual Audit Committee activity and the subsequent election of ten directors.

Evidence limitations

  • The catalog supplies no product-level market shares, customer qualification costs, renewal outcomes, retention rates, price premiums or remaining patent lives sufficient to establish moat width.
  • The competitor-labelled reports describe their respective issuers. They do not establish DuPont's relative product performance or customer dependence; no product-specific named rival is established for the candidate advantage.
  • Regulatory complexity is an operating requirement and potential entry barrier, not demonstrated evidence that DuPont enjoys preferential protection.
  • Operating results are issuer-reported; explanations of their drivers are management attribution. Improved margins alone do not establish a moat.
  • The inge GmbH sales-condition fragments have a retrieval date of 2026-10-19, not a publication date. Their narrow seller scope and incomplete operative conditions do not establish company-wide contractual pricing freedom.
  • Actual executive ownership, ownership-policy compliance, acquisition returns and repurchase value creation remain unestablished. The previous analysis is comparison context only.

Financial indicators to test against the thesis

Calculated from annual filings. Missing data remains unavailable. Detailed financial charts remain in the other topics.

Financial indicators to test against the thesis
PeriodGross marginOperating marginROICFCF margin
202135.1%12.2%3.5%8.3%
202235.5%9.7%2.7%-1.2%
202335.1%3.3%—13.0%
202436.4%10.2%2.8%14.1%
202534.5%2.7%0.4%3.3%

Pricing power—

  • Pricing outcomes

    Second-quarter 2026 organic sales increased 4%, but the definition removes currency and portfolio effects without separating price from volume or mix. The EBITDA explanation also combines growth, mix and productivity. Neither establishes observed price increases or cuts; historical pricing claims in the previous analysis lack current catalog support.

  • Customer demand

    Aggregate growth provides no separation of repeat orders, new customers and market demand. The disclosed regulatory process does not establish customer switching costs. There are no customer cohorts, renewals, engagement measures or sufficiently specific repeat-demand outcomes from which to assess retention indirectly.

  • Margin resilience

    Second-quarter operating EBITDA increased from $423 million in 2025 to $448 million in 2026, and margin rose from 24.2% to 24.6%. Management attributes improvement to organic growth, favorable mix and productivity. This supports partial operating resilience, but neither isolates pricing nor demonstrates performance through a sustained adverse cycle; EBITDA also excludes specified costs.

  • Pricing freedom

    The supplied seller-specific sales-condition fragments do not establish the complete operative repricing terms or their prevalence across DuPont. The disclosure that competitive conditions influence cost pass-through concerns commercial feasibility, not contractual authority. Company-wide ability to reset prices or terms therefore remains unassessable.

Management56

  • Capital discipline

    First-half 2026 continuing operating cash of $632 million exceeded $178 million of capital expenditures. DuPont completed the Aramids sale and a $275 million share repurchase. These demonstrate cash generation and completed capital actions, but not their investment returns; sale consideration also includes a note and non-controlling equity rather than cash alone.

  • Incentive alignment

    Disclosed director share-retention requirements, executive and director hedging restrictions, ownership guidelines, payout caps and clawback controls provide substantive alignment mechanisms. Actual executive holdings, compliance and realized pay-performance sensitivity are not established. These policies support a mixed assessment rather than proof of strong or exceptional alignment in practice.

  • Execution

    Completed Electronics separation and Aramids divestiture demonstrate transaction execution. Second-quarter 2026 organic sales growth of 4%, higher EBITDA and improved first-half continuing cash generation provide indirect operating evidence. The passages do not establish sustained post-separation results or achieved transaction returns, so anticipated strategic benefits receive no credit.

  • Governance

    Annual elections, majority voting and stockholder rights accompany an entirely independent Audit Committee that held eight meetings during 2025 and disclosed private-session practices. Subsequent voting results confirm election of ten directors. These demonstrate strong governance processes, while leaving their effectiveness in preventing poor decisions or misconduct unproven.

Sources and methodology

Current publication · Updated 23/10/2026 · Version 12

AI interpretation based on checked source excerpts. Issuer assertions and evidence limitations remain explicit.

Policy quality-scores-3: six equally weighted categories. The overall score requires full coverage. Missing inputs are not zero. Qualitative grades are sourced interpretations, not probabilities. 4/6 · 31/10/2026

Moat—

Insufficient evidence for every rubric criterion; no category score is inferred.

structural advantage · 1/4 · Contractual access to patents and know-how, together with complex approval requirements, supplies a weak basis for potential differentiation. The passages do not demonstrate exclusion, superior customer outcomes or switching friction. This grade reflects limited evidence of an advantage, not demonstrated competitive inferiority.

durability · — · No remaining patent terms, protected-product economics or sustained customer preference are disclosed. Approval renewal and possible adverse IP decisions identify erosion channels, but do not establish how long an economic advantage currently lasts. A durability grade would require assumptions beyond these passages.

customer dependency · — · Product approval requirements apply to DuPont's right to sell; they do not establish customers' dependence on its products. No customer qualification burden, embedded design relationship, replacement cost or repeat-purchase evidence is supplied. Aggregate sales growth cannot identify those mechanisms.

erosion resilience · — · Recent earnings and margin improvements demonstrate operating progress, but do not show an identified advantage surviving substitution, rival innovation or an adverse IP event. Conditional cost pass-through and IP risks remain relevant possibilities. The catalog cannot distinguish durable competitive resilience from favorable demand, mix and productivity.

Pricing power—

Insufficient evidence for every rubric criterion; no category score is inferred.

realized pricing · — · Second-quarter 2026 organic sales increased 4%, but the definition removes currency and portfolio effects without separating price from volume or mix. The EBITDA explanation also combines growth, mix and productivity. Neither establishes observed price increases or cuts; historical pricing claims in the previous analysis lack current catalog support.

retention · — · Aggregate growth provides no separation of repeat orders, new customers and market demand. The disclosed regulatory process does not establish customer switching costs. There are no customer cohorts, renewals, engagement measures or sufficiently specific repeat-demand outcomes from which to assess retention indirectly.

margin resilience · 2/4 · Second-quarter operating EBITDA increased from $423 million in 2025 to $448 million in 2026, and margin rose from 24.2% to 24.6%. Management attributes improvement to organic growth, favorable mix and productivity. This supports partial operating resilience, but neither isolates pricing nor demonstrates performance through a sustained adverse cycle; EBITDA also excludes specified costs.

contractual freedom · — · The supplied seller-specific sales-condition fragments do not establish the complete operative repricing terms or their prevalence across DuPont. The disclosure that competitive conditions influence cost pass-through concerns commercial feasibility, not contractual authority. Company-wide ability to reset prices or terms therefore remains unassessable.

Predictability63

5 consecutive published annual periods. Equal weights: nondeclining revenue frequency; revenue-growth volatility (5–40pp); positive FCF frequency; FCF-margin volatility (3–20pp). Stability indicator, not a growth forecast.

Nondeclining revenue years (%)
25.00
Revenue growth volatility (pp)
17.81
Positive FCF years (%)
80.00
FCF margin volatility (pp)
5.79
observedAnnualPeriods
5.00

Financial strength25

Equal-weight grades: debt/FCF (1–8x), net debt/earnings before interest and tax (0–5x), interest service (1–12x), current ratio (0.75–2x). Earnings use reported operating income, an original issuer-reported unadjusted EBIT reconciled to net income, income tax and signed net interest, or reported pretax profit plus reported gross interest expense. Reported EBIT is distinct from GAAP operating income and gross interest. Interest service uses earnings/interest expense; if unavailable, it uses reported operating cash flow/cash interest paid, without relabeling cash paid as accrued expense. Nonpositive cash flow/earnings score 0 for their service component; reported zero interest with a positive numerator scores 100. Net cash scores 100 for net leverage. Missing disclosures remain unavailable. General nonfinancial-company rubric, not a credit rating; exceptional and nonoperating gains are not normalized out. IFRS finance-cost and cash-flow classifications retain their reported scope.

debtFcfGrade
0.00
netDebtEbitGrade
0.00
interestCoverageGrade
0.00
currentRatioGrade
100.00
Debt / FCF (x)
14.07
Net debt / operating income (x)
13.33
Interest coverage (x)
0.59
Current ratio (x)
2.42

Capital allocation52

Three-year equal-weight indicators: pretax return on average invested capital (0–25%; equity + debt − cash, each year and its prior year), share-count growth (0–5%, lower better), share-based cost/revenue (2–20%, lower better), consolidated FCF/net income (0–1x). Return uses reported operating income, an original issuer-reported unadjusted EBIT reconciled to net income, income tax and signed net interest, or EBIT calculated from reported pretax profit plus reported gross interest expense; the issuer-reported EBIT is distinct from GAAP operating income and gross interest; exceptional/nonoperating gains are not normalized out. Share-based cost uses the reported cash-flow add-back or, if absent, separately reported recognized compensation expense; the latter never becomes an FCF adjustment. Nonpositive net income scores 0 for cash conversion; absent income/FCF stays unavailable. ROIC remains undefined for nonpositive invested capital; the explicit asset-return alternative does not change the ROIC chart. Missing financial inputs alone never trigger an alternative. Does not establish acquisition quality or buyback timing.

3-year pre-tax operating return (%)
2.13
3-year average dilution (%)
-24.97
3-year average SBC / revenue (%)
0.55
cashConversionGrade
0.00

Management56

Equal-weight average of four evidence-backed rubric grades (0–4), scaled to 100.

capital discipline · 2/4 · First-half 2026 continuing operating cash of $632 million exceeded $178 million of capital expenditures. DuPont completed the Aramids sale and a $275 million share repurchase. These demonstrate cash generation and completed capital actions, but not their investment returns; sale consideration also includes a note and non-controlling equity rather than cash alone.

incentive alignment · 2/4 · Disclosed director share-retention requirements, executive and director hedging restrictions, ownership guidelines, payout caps and clawback controls provide substantive alignment mechanisms. Actual executive holdings, compliance and realized pay-performance sensitivity are not established. These policies support a mixed assessment rather than proof of strong or exceptional alignment in practice.

execution · 2/4 · Completed Electronics separation and Aramids divestiture demonstrate transaction execution. Second-quarter 2026 organic sales growth of 4%, higher EBITDA and improved first-half continuing cash generation provide indirect operating evidence. The passages do not establish sustained post-separation results or achieved transaction returns, so anticipated strategic benefits receive no credit.

governance · 3/4 · Annual elections, majority voting and stockholder rights accompany an entirely independent Audit Committee that held eight meetings during 2025 and disclosed private-session practices. Subsequent voting results confirm election of ten directors. These demonstrate strong governance processes, while leaving their effectiveness in preventing poor decisions or misconduct unproven.

Evidence

•Intellectual Property Cross-License Agreement: The Intellectual Property Cross-License Agreement sets forth the terms and conditions pursuant to which the Company and Qnity may use, following the Qnity Distribution, certain patents, know-how (including trade secrets), copyrights and software contractually allocated to the other party under the Electronics Separation and Distribution Agreement in the conduct of their respective businesses and the natural evolutions thereof.

2026 second-quarter 10-Q, separation agreements: intellectual property cross-license; filed 2026-08-04 · Filed 04/08/2026

In most jurisdictions, DuPont must test the safety, efficacy and environmental impact of the Company’s products to satisfy regulatory requirements and obtain the needed approvals.

2025 10-K, risk factors: product testing and regulatory approvals; filed 2026-02-17 · Filed 17/02/2026

The regulatory approvals process is lengthy, complex and in some markets unpredictable, with requirements that can vary by product, technology, industry and country.

2025 10-K, risk factors: approval-process complexity; filed 2026-02-17 · Filed 17/02/2026

If challenges are resolved adversely, it could negatively impact the Company’s ability to obtain licenses on competitive terms, commercialize new products and generate sales from existing products.

2025 10-K, risk factors: adverse intellectual-property challenges; filed 2026-02-17 · Filed 17/02/2026

In certain jurisdictions, DuPont must periodically renew the Company’s approvals, which may require it to demonstrate compliance with then-current standards.

2025 10-K, risk factors: periodic approval renewal; filed 2026-02-17 · Filed 17/02/2026

Success in offsetting higher raw material costs with price increases is largely influenced by competitive and economic conditions and could vary significantly depending on the market served.

2026 second-quarter 10-Q, risk factors: competitive limits on cost pass-through; filed 2026-08-04 · Filed 04/08/2026

Second Quarter 2026 Consolidated Results(1) Dollars in millions, except EPS 2Q’26 2Q’25 Change vs.

Second-quarter 2026 earnings release, consolidated-results table: period and units; filed 2026-08-04 · Filed 04/08/2026

2Q’25 Organic Sales (2) vs. 2Q’25 Net sales $1,819 $1,749 4% 4% GAAP Income from continuing operations $191 $24 n.m.

Second-quarter 2026 earnings release, consolidated-results table: net sales and organic growth; filed 2026-08-04 · Filed 04/08/2026

Operating EBITDA(2) $448 $423 6% Operating EBITDA margin(2) % 24.6 % 24.2 % 40 bps GAAP EPS from continuing operations $1.37 $0.17 n.m.

Second-quarter 2026 earnings release, consolidated-results table: operating EBITDA and margin; filed 2026-08-04 · Filed 04/08/2026

•Operating EBITDA and margin increased on organic growth, favorable mix and productivity.

Second-quarter 2026 earnings release, operating EBITDA drivers; filed 2026-08-04 · Filed 04/08/2026

6 Non-GAAP Measure Definitions Organic Sales Organic Sales is defined as net sales excluding the impacts of currency and portfolio.

Second-quarter 2026 earnings release, non-GAAP definitions: organic sales; filed 2026-08-04 · Filed 04/08/2026

Reconciliation of "Cash provided by operating activities - continuing operations" to Adjusted Free Cash Flow 1 , Transaction-Adjusted Free Cash Flow1 and calculation of "Adjusted Free Cash Flow Conversion" and "Transaction-Adjusted Free Cash Flow Conversion" Three Months Ended Six Months Ended In millions (Unaudited) Jun 30, 2026 Jun 30, 2025 Jun 30, 2026 Jun 30, 2025 Cash provided by operating activities (GAAP) 2 - continuing operations $ 400 $ 74 $ 632 $ 151 Capital expenditures (76) (50) (178) (172) Adjusted free cash flow (non-GAAP) $ 324 $ 24 $ 454 $ (21) Separation-related transaction cost and other payments3 2 83 19 136 Transaction-adjusted free cash flow (non-GAAP) $ 326 $ 107 $ 473 $ 115 Adjusted earnings (non-GAAP) 4 $ 257 $ 177 $ 483 $ 331 Adjusted free cash flow conversion (non-GAAP) 126 % 14 % 94 % (6) % Transaction-adjusted free cash flow conversion (non-GAAP) 127 % 60 % 98 % 35 % 1.Adjusted Free Cash Flow and Transaction-Adjusted Free Cash Flow are calculated on a continuing operations basis for all periods presented.

Second-quarter 2026 earnings release, cash-flow reconciliation: periods, millions and continuing-operations scope; filed 2026-08-04 · Filed 04/08/2026

On April 1, 2026, DuPont completed the sale of the Aramids business (the "Aramids Business" and the divestiture of the Aramids Business, the "Aramids Divestiture") to Arclin, a portfolio company of an affiliate of TJC LP for pre-tax cash proceeds of approximately $1.2 billion, subject to customary transaction adjustments, a note receivable in the principal amount of $300 million (the "Aramids Note Receivable") and a non-controlling common equity interest (the "Aramids Equity Consideration"), valued at $325 million, in New Arclin U.S.

2026 second-quarter 10-Q, overview: completed Aramids sale and consideration; filed 2026-08-04 · Filed 04/08/2026

In May 2026, DuPont entered into an ASR agreement with one counterparty for the repurchase of approximately $275 million of common stock ("Q2 2026 ASR Transaction").

2026 second-quarter 10-Q, equity: Q2 2026 accelerated share repurchase agreement; filed 2026-08-04 · Filed 04/08/2026

The Q2 2026 ASR Transaction resulted in delivery of approximately 1.8 million shares of DuPont common stock, at an average price of $148.91 per share, which were retired immediately and recorded as an increase of $270 million to "Accumulated Deficit" in the Consolidated Statements of Equity.

2026 second-quarter 10-Q, equity: completed repurchase and retirement; filed 2026-08-04 · Filed 04/08/2026

on November 1, 2025 (the “Effective Time”), DuPont de Nemours, Inc., a Delaware corporation (the “Company”), completed the previously announced separation of the Company’s Electronics business, Qnity Electronics, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Qnity”), into a separate and independent public company (the “Separation”) through a pro rata dividend in-kind of all of the then-issued and outstanding shares of Qnity’s common stock, par value $0.01 per share (the “Qnity Common Stock”), to holders of the Company’s common stock, par value $0.01 per share (the “Company Common Stock”), as of the close of business on October 22, 2025 (the “Distribution”).

Electronics separation 8-K, completed distribution on 2025-11-01; filed 2025-11-03 · Filed 03/11/2025

nominees are independent Independent Board Committees Annual Board elections Directors are elected by a majority of votes cast Directors not elected by a majority of votes cast are subject to the Company’s resignation policy Independent directors meet in executive session without management at each regularly scheduled Board meeting Annual Board and Committee self- evaluations Annual director evaluations Retirement policy Directors are required to hold Company granted shares until retirement Executives and directors prohibited from hedging or pledging Company stock Stockholder right to call special meetings No super- majority stockholder voting requirements Eligible stockholders are able to nominate directors through proxy access Executive Compensation Our executive compensation philosophy and practices reflect a commitment to paying for performance — both short-term and long- term.

2026 proxy, governance practices: elections, stockholder rights, director share retention and trading restrictions; filed 2026-04-10 · Filed 10/04/2026

The evaluation covered a wide range of practices, including the balanced mix between pay elements, the balanced mix between short-term and long-term programs, caps on incentive payouts, governance controls in place to establish, review and approve goals, use of multiple performance measures, discretion on individual awards, use of stock ownership guidelines, provisions in severance/change in control policies, use of a clawback policy, and Committee oversight of compensation programs.

2026 proxy, compensation risk review: incentive controls, ownership guidelines and clawback policy; filed 2026-04-10 · Filed 10/04/2026

The Audit Committee of the Board is comprised entirely of independent directors who meet the independence, experience and other qualification requirements of the New York Stock Exchange (“NYSE”) and the Company’s Corporate Governance Guidelines.

2026 proxy, Audit Committee report: actual committee independence; filed 2026-04-10 · Filed 10/04/2026

The Audit Committee held eight meetings during 2025.

2026 proxy, Audit Committee report: eight meetings during 2025; filed 2026-04-10 · Filed 10/04/2026

Unless determined unnecessary by the Committee, these meetings also included executive sessions among the Committee members only and separate, private sessions between the Committee and a) one or more of the independent registered public accounting firm’s client service partners and the lead engagement partner, b) the General Auditor, and c) the CFO.

2026 proxy, Audit Committee report: private-session practices and qualification; filed 2026-04-10 · Filed 10/04/2026

The Company’s stockholders elected the following 10 nominees to serve on the Board of Directors of the Company until the next annual meeting of stockholders or until their successors have been duly elected and qualified.

Annual-meeting results 8-K, election of ten directors; filed 2026-05-26 · Filed 26/05/2026

The Company defines Operating EBITDA as earnings (i.e., “Income from continuing operations before income taxes") before interest, depreciation, amortization, non-operating pension / OPEB benefits / charges, and foreign exchange gains / losses, excluding Future Reimbursable Indirect Costs, environmental remediation costs, including certain investigate, remediate and restoration costs, associated with discontinued or divested operations, businesses or product lines (“Corporate DDOB Remediation Costs”), and is adjusted for significant items.

2026 first-quarter 10-Q, segment reporting: operating EBITDA definition and exclusions; filed 2026-05-05 · Filed 05/05/2026

Publication history

Publication history
VersionUpdatedCompetitive advantage
1231/10/2026uncertain
1128/10/2026uncertain
1028/10/2026uncertain
924/10/2026uncertain
823/10/2026uncertain
722/10/2026uncertain
619/10/2026uncertain
519/10/2026uncertain
419/10/2026uncertain
318/10/2026uncertain

Sources

Research methodology and limitations · What is an economic moat?